SCHEMBL31725232

SCHEMBL31725232

COC(=O)c1ccc(C(C)O[Si](C)(C)C(C)(C)C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.43
CA2 P00918 4/20 0.43
CA12 O43570 3/20 0.43
CA9 Q16790 3/20 0.43
CA14 Q9ULX7 3/20 0.43
CA7 P43166 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
TSHR P16473 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPT P10636 4/20 0.40
RAB9A P51151 2/20 0.40
NOTUM Q6P988 1/20 0.40
ALDH1A1 P00352 1/20 0.40
XDH P47989 1/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31073356 1.00 CA1 (0.43) CA1CA2CA12CA9CA14
SCHEMBL31073290 1.00 CA1 (0.43) CA1CA2CA12CA9CA14
SCHEMBL9338170 0.83 ALDH1A1 (0.32) ALDH1A1
SCHEMBL6093810 0.80 CA1 (0.39) CA1CA2CA12CA9CA14
SCHEMBL18210606 0.80 CYP3A4 (0.38) CA1CA2CA12CA9CA14
SCHEMBL8880538 0.79 ESR1 (0.43) TSHRCYP2C9CYP2C19ALDH1A1
SCHEMBL8686880 0.78 NPC1 (0.42) RAB9ANPC1MEN1KMT2A
SCHEMBL10514359 0.78
SCHEMBL31541700 0.77 CA1 (0.55) CA1CA2CA12CA9CA14
SCHEMBL31541673 0.77 CA1 (0.55) CA1CA2CA12CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKA, DGKK CA1 3930/4885CA2 3679/4885CA12 4738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.